Fly News Breaks for January 8, 2020
Jan 8, 2020 | 07:04 EDT
Goldman Sachs analyst Graig Suvannavejh initiated coverage of Jazz Pharmaceuticals with a Neutral rating and $153 price target. The analyst believes Jazz's narcolepsy franchise is sustainable and believes that the patent cliff can be successfully managed. However, given the company's decelerating growth trends, he finds the stock fairly valued and prefers opportunities elsewhere in the sector.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ